SAL Trading’s GSK GSK Stock Holding History

SAL Trading’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-7,000	Closed	-$254K	–	30
2023 Q3	$254K	Buy	+7,000	New	+$248K	0.36%	24

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SAL Trading's GSK Position: Q4 2023 in Review

SAL Trading sold out of GSK (GSK) in Q4 2023, closing a stake of 7,000 shares — an estimated $254K sold.

SAL Trading first reported a position in GSK in Q3 2023 and held it in 1 quarter. The position peaked at $254K in Q3 2023. 896 funds tracked by Wall St. Rank hold GSK as of Q4 2023.

SAL Trading reported no remaining GSK position as of Q4 2023 after selling out during the quarter.
SAL Trading sold 7,000 GSK shares in Q4 2023, an estimated $254K.
SAL Trading first reported a position in GSK in Q3 2023 and held it in 1 quarter.
SAL Trading's GSK position peaked at $254K in Q3 2023.
896 funds tracked by Wall St. Rank held GSK as of Q4 2023.

Based on SAL Trading's 13F filing for Q4 2023, filed 14 Feb 2024.